Format

Send to

Choose Destination
JAMA. 2014 Jan 8;311(2):193-4. doi: 10.1001/jama.2013.283787.

Pharmacological treatments for smoking cessation.

Author information

1
Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom2Cochrane Tobacco Addiction Group, University of Oxford, Oxford, United Kingdom.
2
Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.

Abstract

CLINICAL QUESTION:

Among the 3 first-line smoking cessation treatments (nicotine replacement therapy [NRT], bupropion, and varenicline), which is most effective in helping people who smoke achieve and maintain abstinence from smoking for at least 6 months, and what serious adverse events are associated with each?

BOTTOM LINE:

Higher rates of smoking cessation were associated with NRT (17.6%) and bupropion (19.1%) compared with placebo (10.6%). Varenicline (27.6%) and combination NRT (31.5%) (eg, patch plus inhaler) were most effective for achieving smoking cessation. None of the therapies was associated with an increased rate of serious adverse events.

PMID:
24399558
DOI:
10.1001/jama.2013.283787
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center